A pilot study of CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] plus Campath [alemtuzumab] for the primary treatment of ALK-ve [anaplastic lymphoma kinase-negative] peripheral T cell lymphoma [non-Hodgkin's lymphoma]

Trial Profile

A pilot study of CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] plus Campath [alemtuzumab] for the primary treatment of ALK-ve [anaplastic lymphoma kinase-negative] peripheral T cell lymphoma [non-Hodgkin's lymphoma]

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2006

At a glance

  • Drugs Alemtuzumab; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Dec 2006 Status change
    • 05 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top